| Autor: |
Atar S; Department of Cardiovascular Medicine, The Western Galilee Hospital in Nahariya, Nahariya; Faculty of Medicine of the Galilee, Bar Ilan University, Safed. Electronic address: shaul.atar@gmail.com., Wishniak A; Department of Cardiovascular Medicine, The Western Galilee Hospital in Nahariya, Nahariya., Shturman A; Department of Cardiovascular Medicine, The Western Galilee Hospital in Nahariya, Nahariya; Faculty of Medicine of the Galilee, Bar Ilan University, Safed., Shtiwi S; Department of Cardiothoracic Surgery, Lady Davis Carmel Medical Center, Haifa, Israel., Brezins M; Department of Cardiovascular Medicine, The Western Galilee Hospital in Nahariya, Nahariya; Faculty of Medicine of the Galilee, Bar Ilan University, Safed. |
| Abstrakt: |
Several new oral anticoagulants have been approved for thromboembolism prevention in patients with nonvalvular atrial fibrillation. However, they are not yet approved for anticoagulation use in patients with prosthetic mechanical valves, and no randomized data have been published so far on their safety of use in these patients. We present two cases of patients with prosthetic mechanical mitral valves who were switched from warfarin and acenocoumarol to dabigatran and within 1 month experienced severe valve complications resulting in death. One patient experienced stroke and later cardiogenic shock and death, and the other experienced pulmonary edema, cardiogenic shock, and subsequent death. |
